GlassScriptPhysician profile
Lorilee A Perry
NPI 1083924906
$3,744.01
in general payments reported to CMS, 2019-2025
27 companies · $1,365 in 2025
The $1,365 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $865 · 2022: $843 · 2023: $67.78 · 2024: $603 · 2025: $1,365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,036.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,035.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $943.25 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $457.10 | 2021-2025 | Jardiance, Ofev |
| Astrazeneca Pharmaceuticals LP | $355.21 | 2021-2025 | Breztri, Farxiga |
| Lilly USA, LLC | $261.26 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $212.35 | 2021-2025 | Xifaxan |
| Amgen INC. | $199.61 | 2021-2024 | Otezla, Repatha |
| Novo Nordisk INC | $180.79 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $164.39 | 2021-2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $143.78 | 2024-2025 | |
| Exact Sciences Corporation | $132.20 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Eisai INC. | $125.00 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $111.75 | 2021 | |
| Boston Scientific Corporation | $83.18 | 2022 | |
| Pfizer INC. | $48.64 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $43.47 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $39.83 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $36.13 | 2023 | Dysport |
| Abbott Laboratories | $27.76 | 2022 | |
| Krystal Biotech INC | $27.10 | 2025 | Vyjuvek |
| Xeris Pharmaceuticals, INC. | $25.22 | 2024 | Gvoke Hypopen |
| Hologic Sales and Service, LLC | $24.15 | 2025 | Aptima, Thinprep 2000 Processor |
| Inspire Medical Systems, INC. | $22.70 | 2025 | Inspire |
| Medtronic, INC. | $20.61 | 2025 | Inceptiv |
| Globus Medical, INC. | $18.56 | 2025 | Senza |
| Ironwood Pharmaceuticals, INC | $17.33 | 2022 | |
| Esperion Therapeutics, INC. | $14.51 | 2024 | Nexletol |
| Mayne Pharma Commercial LLC | $8.13 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorilee Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.